Liquid Biopsies, What We Do Not Know (Yet)

Alberto Bardelli; Klaus Pantel

doi:10.1016/j.ccell.2017.01.002

Liquid Biopsies, What We Do Not Know (Yet)

Standard

Liquid Biopsies, What We Do Not Know (Yet). / Bardelli, Alberto; Pantel, Klaus.

In: CANCER CELL, Vol. 31, No. 2, 13.02.2017, p. 172-179.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bardelli, A & Pantel, K 2017, 'Liquid Biopsies, What We Do Not Know (Yet)', CANCER CELL, vol. 31, no. 2, pp. 172-179. https://doi.org/10.1016/j.ccell.2017.01.002

APA

Bardelli, A., & Pantel, K. (2017). Liquid Biopsies, What We Do Not Know (Yet). CANCER CELL, 31(2), 172-179. https://doi.org/10.1016/j.ccell.2017.01.002

Vancouver

Bardelli A, Pantel K. Liquid Biopsies, What We Do Not Know (Yet). CANCER CELL. 2017 Feb 13;31(2):172-179. https://doi.org/10.1016/j.ccell.2017.01.002

Bibtex

@article{c732ffa889344500b07541276e4304da,

title = "Liquid Biopsies, What We Do Not Know (Yet)",

abstract = "The inherent molecular heterogeneity of metastatic tumors and the ability of cancer genomes to dynamically evolve are not properly captured by tissue specimens. Analysis of cell-free DNA and circulating tumor cells has the potential to change clinical practice by exploiting blood rather than tissue as a source of information. Liquid biopsies are already used to monitor disease response and track the emergence of drug resistance. The suitability of blood-based molecular profiles for early detection and monitoring minimal residual disease is being evaluated. In this review, we address open questions in this fast-evolving field of research.",

keywords = "Journal Article, Review",

author = "Alberto Bardelli and Klaus Pantel",

year = "2017",

month = feb,

day = "13",

doi = "10.1016/j.ccell.2017.01.002",

language = "English",

volume = "31",

pages = "172--179",

journal = "CANCER CELL",

issn = "1535-6108",

publisher = "Cell Press",

number = "2",

}

RIS

TY - JOUR

T1 - Liquid Biopsies, What We Do Not Know (Yet)

AU - Bardelli, Alberto

AU - Pantel, Klaus

PY - 2017/2/13

Y1 - 2017/2/13

N2 - The inherent molecular heterogeneity of metastatic tumors and the ability of cancer genomes to dynamically evolve are not properly captured by tissue specimens. Analysis of cell-free DNA and circulating tumor cells has the potential to change clinical practice by exploiting blood rather than tissue as a source of information. Liquid biopsies are already used to monitor disease response and track the emergence of drug resistance. The suitability of blood-based molecular profiles for early detection and monitoring minimal residual disease is being evaluated. In this review, we address open questions in this fast-evolving field of research.

AB - The inherent molecular heterogeneity of metastatic tumors and the ability of cancer genomes to dynamically evolve are not properly captured by tissue specimens. Analysis of cell-free DNA and circulating tumor cells has the potential to change clinical practice by exploiting blood rather than tissue as a source of information. Liquid biopsies are already used to monitor disease response and track the emergence of drug resistance. The suitability of blood-based molecular profiles for early detection and monitoring minimal residual disease is being evaluated. In this review, we address open questions in this fast-evolving field of research.

KW - Journal Article

KW - Review

U2 - 10.1016/j.ccell.2017.01.002

DO - 10.1016/j.ccell.2017.01.002

M3 - SCORING: Journal article

C2 - 28196593

VL - 31

SP - 172

EP - 179

JO - CANCER CELL

JF - CANCER CELL

SN - 1535-6108

IS - 2

ER -